Autosomal Dominant Polycystic Kidney Disease
Symptoms, Doctors, Treatments, Advances & More

Autosomal Dominant Polycystic Kidney Disease Overview

Save information for later
Sign Up

Learn About Autosomal Dominant Polycystic Kidney Disease

What is the definition of Autosomal Dominant Polycystic Kidney Disease?
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. ADPKD is a progressive disease and symptoms tend to get worse over time. The most common symptoms are kidney cysts, pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, and brain aneurysms. ADPKD is most often caused by changes in the PKD1 and PKD2 genes, and less often by changes in the GANAB and DNAJB11 genes. It is inherited in a dominant pattern. ADPKD is the most common inherited disorder of the kidneys.
What are the alternative names for Autosomal Dominant Polycystic Kidney Disease?
  • Autosomal dominant polycystic kidney disease
  • ADPKD
  • Polycystic kidney disease, adult type
Who are the top Autosomal Dominant Polycystic Kidney Disease Local Doctors?
Elite in Autosomal Dominant Polycystic Kidney Disease
Elite in Autosomal Dominant Polycystic Kidney Disease
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
888-824-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Arlene Chapman is a Nephrologist practicing medicine in Chicago, Illinois. Dr. Chapman is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Disease, Tuberous Sclerosis, and Kidney Transplant. Dr. Chapman is board certified in Practicing Since1986 and Internal Medicine Nephrology. Dr. Chapman is currently accepting new patients.

Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Alan S. Yu
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Alan S. Yu
Nephrology
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
913-588-1227
Languages Spoken:
English, Cantonese
See accepted insurances
Accepting New Patients
Offers Telehealth

Alan Yu is a Nephrologist practicing medicine in Kansas City, Kansas. Dr. Yu is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Disease, and Kidney Stones. Dr. Yu is board certified in American Board Of Internal Medicine, Internal Medicine - 1995 and American Board Of Internal Medicine, Nephrology - 1996 . Dr. Yu is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Autosomal Dominant Polycystic Kidney Disease
Elite in Autosomal Dominant Polycystic Kidney Disease
Referral may be required

Nephrology And Hypertension Faculty Practice

400 Parnassus Ave., B1 Plaza Level, 
San Francisco, CA 
415-353-2507
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Meyeon Park is a Nephrologist practicing medicine in San Francisco, California. Dr. Park is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Liddle Syndrome, Pseudohypoaldosteronism Type 2, and Kidney Transplant. Dr. Park is board certified in American Board Of Internal Medicine, Nephrology and American Board Of Internal Medicine, Internal Medicine. Dr. Park is currently accepting new patients.

View All Doctors
What are the latest Autosomal Dominant Polycystic Kidney Disease Clinical Trials?
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed i...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Asceding Doses of GV-100 With Food-Effect and Drug Drug Interaction Evaluations in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Asceding Doses of GV-100 With Food-Effect and Drug Drug Interaction Evaluations in Healthy Participants
Enrollment Status: Recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy participants. The study is divided into four parts: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Food Effect (FE), and Drug-Drug Interaction (DDI).

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center